SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2025)
Historic Enterprise Value for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to -$110.9 million.
- SAB Biotherapeutics' Enterprise Value fell 26438.57% to -$110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.9 million, marking a year-over-year decrease of 26438.57%. This contributed to the annual value of -$20.8 million for FY2024, which is 6329.83% up from last year.
- Per SAB Biotherapeutics' latest filing, its Enterprise Value stood at -$110.9 million for Q3 2025, which was down 26438.57% from -$5.7 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Enterprise Value registered a high of -$2.4 million during Q3 2023, and its lowest value of -$110.9 million during Q3 2025.
- In the last 5 years, SAB Biotherapeutics' Enterprise Value had a median value of -$16.6 million in 2022 and averaged -$25.5 million.
- As far as peak fluctuations go, SAB Biotherapeutics' Enterprise Value tumbled by 115457.53% in 2024, and later surged by 8469.29% in 2025.
- SAB Biotherapeutics' Enterprise Value (Quarter) stood at -$39.5 million in 2021, then skyrocketed by 61.95% to -$15.0 million in 2022, then tumbled by 275.93% to -$56.6 million in 2023, then surged by 63.3% to -$20.8 million in 2024, then plummeted by 434.09% to -$110.9 million in 2025.
- Its Enterprise Value was -$110.9 million in Q3 2025, compared to -$5.7 million in Q2 2025 and -$12.9 million in Q1 2025.